|
|
|
|
| LEADER |
01906nam a2200325 u 4500 |
| 001 |
EB001865406 |
| 003 |
EBX01000000000000001029486 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
190504 r ||| eng |
| 245 |
0 |
0 |
|a Pharmacoeconomic review report: Empagliflozin and Metformin fixed-dose combination (Synjardy)
|h Elektronische Ressource
|
| 246 |
3 |
1 |
|a Empagliflozin and Metformin fixed-dose combination (Synjardy)
|
| 246 |
3 |
1 |
|a CDR pharmacoeconomic review report for Synjardy
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c September 2017, 2017
|
| 300 |
|
|
|a 1 PDF file (16 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Drug Combinations
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Glucosides
|
| 653 |
|
|
|a Metformin
|
| 653 |
|
|
|a Diabetes Mellitus, Type 2 / drug therapy
|
| 653 |
|
|
|a Hypoglycemic Agents / economics
|
| 653 |
|
|
|a Sodium-Glucose Transporter 2 Inhibitors
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK532803
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a Empagliflozin (EMPA)/metformin (MET) fixed-dose combination (FDC) tablet (Synjardy) is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus (T2DM) inadequately controlled on MET alone, MET and a sulfonylurea (SU), MET and pioglitazone (PIO), or MET and insulin; or when EMPA and MET are already being co-administered as separate tablets with or without an SU, PIO, or insulin. The manufacturer is seeking reimbursement for adult patients with T2DM who are already stabilized on therapy with MET and EMPA, to replace the individual components
|